Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProPhase Labs, Inc.PRPH · Entity 8699 | Chief Operating Officer | February 17, 2025 | February 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProPhase Labs, Inc.
Report date February 17, 2025 · Filed February 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2032-02-17 | Direct | 500,000 |
Reported balance
After 2025-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-17 · Grant · Acquired 500,000 · Balance 500,000 F1: Stock option granted as an inducement award. The option vests over a three-year period, with 25% vesting on the date of grant and 25% vesting on each of the next three anniversaries thereafter, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option granted as an inducement award. The option vests over a three-year period, with 25% vesting on the date of grant and 25% vesting on each of the next three anniversaries thereafter, subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2025 Filed Feb 21, 2025 22:15 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-25-007918 · ownership.xml · derivative · entry 1 Hollenshead Stuart · CIK 0002057407 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-02-17 F1 · security: Stock option granted as an inducement award. The option vests over a three-year period, with 25% vesting on the date of grant and 25% vesting on each of the next three anniversaries thereafter, subject to the Reporting Person's continued service through each vesting date. F1 · derivative.exercise_date: Stock option granted as an inducement award. The option vests over a three-year period, with 25% vesting on the date of grant and 25% vesting on each of the next three anniversaries thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.